Marc Blockman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marc Blockman has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Karen Cohen
Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
6 shared publications - Catriona Waitt
Department of Pharmacology and Therapeutics University of Liverpool Liverpool UK
4 shared publications - Gayle Tatz
Division of Clinical Pharmacology; University of Cape Town; Cape Town South Africa
4 shared publications - Munir Pirmohamed
University of Liverpool Department of Pharmacology and Therapeutics
4 shared publications - Briony Sue Chisholm
Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
3 shared publications - Christine Sekaggya-Wiltshire
Makerere University Infectious Diseases Institute Department of Research Kampala
3 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70599
Pharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data
Mycophenolic acid (MPA) is a potent antiproliferative immunosuppressive agent used to prevent organ transplant rejection and to treat various immune‐mediated diseases. MPA is the active metabolite formed from the biotransformation of the prodrugs mycophenolate mofetil (MMF) or enteric‐coated mycophenolate sodium (EC‐MPS). MPA exerts its therapeutic effects by inhibiting guanosine nucleotide synthesis in lymphocytes. Through this inhibition, cell and humoral immunity is suppressed, resulting in a reduction of cytotoxicity and inflammation. Systemic exposure to MPA is influenced by a complex pharmacokinetic pathway, which involves various drug‐metabolizing enzymes (DMEs) and transporters. Substantial interindividual variability exists in MPA exposure, efficacy, and adverse effects. Genetic polymorphisms in the genes encoding DMEs and transporters have been reported to influence this observed variability; however, evidence remains inconsistent and is largely derived from non‐African populations. African populations exhibit high levels of genetic diversity, and their underrepresentation in pharmacogenetic studies may hinder the identification of important variants influencing MPA disposition and clinical outcomes. This review evaluates the genes that have been reported to affect MPA exposure as well as highlights conflicting results on the role of these pharmacogenetic variants in different populations. The review highlights the lack of data on African populations and provides justification for their inclusion in the study of MPA pharmacogenetics.
- 15 May 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70599
Open AccessPharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data
Mycophenolic acid (MPA) is a potent antiproliferative immunosuppressive agent used to prevent organ transplant rejection and to treat various immune‐mediated diseases. MPA is the active metabolite formed from the biotransformation of the prodrugs mycophenolate mofetil (MMF) or enteric‐coated mycophenolate sodium (EC‐MPS). MPA exerts its therapeutic effects by inhibiting guanosine nucleotide synthesis in lymphocytes. Through this inhibition, cell and humoral immunity is suppressed, resulting in a reduction of cytotoxicity and inflammation. Systemic exposure to MPA is influenced by a complex pharmacokinetic pathway, which involves various drug‐metabolizing enzymes (DMEs) and transporters. Substantial interindividual variability exists in MPA exposure, efficacy, and adverse effects. Genetic polymorphisms in the genes encoding DMEs and transporters have been reported to influence this observed variability; however, evidence remains inconsistent and is largely derived from non‐African populations. African populations exhibit high levels of genetic diversity, and their underrepresentation in pharmacogenetic studies may hinder the identification of important variants influencing MPA disposition and clinical outcomes. This review evaluates the genes that have been reported to affect MPA exposure as well as highlights conflicting results on the role of these pharmacogenetic variants in different populations. The review highlights the lack of data on African populations and provides justification for their inclusion in the study of MPA pharmacogenetics.
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 4 (1)
The evidence-informed decision-making process of the National Essential Medicines List Committee and Essential Drugs Programme
- 1 January 2026
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 4 (1)
Open AccessThe evidence-informed decision-making process of the National Essential Medicines List Committee and Essential Drugs Programme
- Open Access
- 1 July 2025
- Published by Elsevier in African Journal of Emergency Medicine
- Vol. 15 (3) , 100881
A systematic review and meta-analysis of noradrenaline compared to adrenaline in the management of septic shock
- 1 July 2025
- Published by Elsevier in African Journal of Emergency Medicine
- Vol. 15 (3) , 100881
Open AccessA systematic review and meta-analysis of noradrenaline compared to adrenaline in the management of septic shock
- Open Access
- 1 April 2025
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 115 (3) , e2651
Severe lithium-induced nephrogenic diabetes insipidus: The diuresis paradox
We report a case of profound nephrogenic diabetes insipidus (NDI) in which renal resistance to antidiuretic hormone results in dilute polyuria despite normal circulating concentrations. A 28-year-old man with bipolar mood disorder presented to his local clinic with symptoms suggestive of lithium toxicity. Plasma lithium concentrations and thyroid-stimulating hormone (TSH) were taken, but results were not acted upon. One week later, he presented obtunded, severely dehydrated and in renal failure. His plasma lithium concentration was 4.3 mmol/L (toxic threshold >1.5 mmol/L) and TSH >100 mIU/L. After admission to the intensive care unit, including haemodialysis and 12 days of ventilation, he developed profound polyuria, with a peak output of 15 L/day. Amiloride with hydrochlorothiazide adequately reduced the polyuria. Management of lithium-induced NDI remains complex, and includes diuretics, which paradoxically reduce polyuria in this setting. Failure to follow up critical results led to profound morbidity, and is a crucial learning point in this case.
- 1 April 2025
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 115 (3) , e2651
Open AccessSevere lithium-induced nephrogenic diabetes insipidus: The diuresis paradox
We report a case of profound nephrogenic diabetes insipidus (NDI) in which renal resistance to antidiuretic hormone results in dilute polyuria despite normal circulating concentrations. A 28-year-old man with bipolar mood disorder presented to his local clinic with symptoms suggestive of lithium toxicity. Plasma lithium concentrations and thyroid-stimulating hormone (TSH) were taken, but results were not acted upon. One week later, he presented obtunded, severely dehydrated and in renal failure. His plasma lithium concentration was 4.3 mmol/L (toxic threshold >1.5 mmol/L) and TSH >100 mIU/L. After admission to the intensive care unit, including haemodialysis and 12 days of ventilation, he developed profound polyuria, with a peak output of 15 L/day. Amiloride with hydrochlorothiazide adequately reduced the polyuria. Management of lithium-induced NDI remains complex, and includes diuretics, which paradoxically reduce polyuria in this setting. Failure to follow up critical results led to profound morbidity, and is a crucial learning point in this case.
- Open Access
- 6 March 2025
- Published by Elsevier in Nurse Education in Practice
- Vol. 86, 104326
Effectiveness and uptake of WhatsApp-based HIV microlearning for healthcare workers in remote South African clinics: A pragmatic, mixed-methods, cluster-randomised trial
- 6 March 2025
- Published by Elsevier in Nurse Education in Practice
- Vol. 86, 104326
Open AccessEffectiveness and uptake of WhatsApp-based HIV microlearning for healthcare workers in remote South African clinics: A pragmatic, mixed-methods, cluster-randomised trial
- Open Access
- 22 January 2025
- Published by Springer Nature in Drug Safety
- Vol. 48 (3) , 233-249
Empowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management Group
Introduction The COVID-19 pandemic accelerated new vaccine development. Limited safety data necessitated robust global safety surveillance to accurately identify and promptly communicate potential safety issues. The African Union Smart Safety Surveillance (AU-3S) program established the Joint Signal Management (JSM) group to support identification of potential vaccine safety concerns in five pilot countries (Ethiopia, Ghana, Kenya, Nigeria, South Africa), accounting for approximately 35% of the African population. Objective Our objective was to provide an overview of the JSM group’s role in supporting signal management activities for the AU-3S program during the COVID-19 pandemic. Methods Spontaneous, electronically reported COVID-19 vaccine adverse events following immunization (AEFI) from each country's safety data were integrated into the interim Data Integration and Signal Detection system. Statistical disproportionality methods were used to identify and review vaccine–event combinations (VECs) for potential safety concerns. The JSM group—which comprised pharmacovigilance and subject matter experts from National Medicine Regulatory Authorities, Expanded Programs on Immunization, and vaccine safety committees—conducted signal detection activities on cross-country safety data and provided recommendations. Results From April 2021 to December 2023, a total of 48,294 spontaneously reported AEFI were analyzed for six COVID-19 vaccines (NRVV Ad [ChAdOx1 nCoV-19]; Ad26.COV2.S; Elasomeran; Tozinameran; Covid-19 vaccine [Vero Cell], Inactivated; NRVV Ad26 [Gam-Covid-Vac]) administered in Ethiopia (34.6%), Nigeria (30.3%), South Africa (16.9%), Ghana (13.5%), and Kenya (4.7%). Overall, 2,742 VECs were validated. A causal association between the COVID-19 vaccines and the reported AEFI cannot be inferred, as data were reported spontaneously. JSM group recommendations included monitoring for further evidence, no immediate action required, engaging marketing authorization holder(s) for additional information, or sensitizing healthcare providers and/or the public about events. Although no new safety signals were identified, nine safety-related recommendations were issued, including patient and healthcare provider education. Conclusions The JSM group established a scalable and replicable model for future signal management of other priority health products in low- and middle-income countries, fostering ongoing collaboration and capacity building. Knowledge and experience gained from this pilot initiative will guide stakeholders in future safety surveillance initiatives within the African continent.
- 22 January 2025
- Published by Springer Nature in Drug Safety
- Vol. 48 (3) , 233-249
Open AccessEmpowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management Group
Introduction The COVID-19 pandemic accelerated new vaccine development. Limited safety data necessitated robust global safety surveillance to accurately identify and promptly communicate potential safety issues. The African Union Smart Safety Surveillance (AU-3S) program established the Joint Signal Management (JSM) group to support identification of potential vaccine safety concerns in five pilot countries (Ethiopia, Ghana, Kenya, Nigeria, South Africa), accounting for approximately 35% of the African population. Objective Our objective was to provide an overview of the JSM group’s role in supporting signal management activities for the AU-3S program during the COVID-19 pandemic. Methods Spontaneous, electronically reported COVID-19 vaccine adverse events following immunization (AEFI) from each country's safety data were integrated into the interim Data Integration and Signal Detection system. Statistical disproportionality methods were used to identify and review vaccine–event combinations (VECs) for potential safety concerns. The JSM group—which comprised pharmacovigilance and subject matter experts from National Medicine Regulatory Authorities, Expanded Programs on Immunization, and vaccine safety committees—conducted signal detection activities on cross-country safety data and provided recommendations. Results From April 2021 to December 2023, a total of 48,294 spontaneously reported AEFI were analyzed for six COVID-19 vaccines (NRVV Ad [ChAdOx1 nCoV-19]; Ad26.COV2.S; Elasomeran; Tozinameran; Covid-19 vaccine [Vero Cell], Inactivated; NRVV Ad26 [Gam-Covid-Vac]) administered in Ethiopia (34.6%), Nigeria (30.3%), South Africa (16.9%), Ghana (13.5%), and Kenya (4.7%). Overall, 2,742 VECs were validated. A causal association between the COVID-19 vaccines and the reported AEFI cannot be inferred, as data were reported spontaneously. JSM group recommendations included monitoring for further evidence, no immediate action required, engaging marketing authorization holder(s) for additional information, or sensitizing healthcare providers and/or the public about events. Although no new safety signals were identified, nine safety-related recommendations were issued, including patient and healthcare provider education. Conclusions The JSM group established a scalable and replicable model for future signal management of other priority health products in low- and middle-income countries, fostering ongoing collaboration and capacity building. Knowledge and experience gained from this pilot initiative will guide stakeholders in future safety surveillance initiatives within the African continent.
- Open Access
- 9 October 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (20) , 5248-5261
Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry
Warfarin dose requirements are highly variable because of clinical and genetic factors. Although genetic variants influencing warfarin dose have been identified in European and East Asian populations, more work is needed to identify African-specific genetic variants to help optimize warfarin dosing. We performed genome-wide association studies (GWASs) in 4 African cohorts from Uganda, South Africa, and Zimbabwe, totaling 989 warfarin-treated participants who reached stable dose and had international normalized ratios within therapeutic ranges. We also included 2 African American cohorts recruited by the International Warfarin Pharmacogenetics Consortium (n = 316) and the University of Alabama at Birmingham (n = 199). After the GWAS, we performed standard error-weighted meta-analyses and then conducted stepwise conditional analyses to account for known loci in chromosomes 10 and 16. The genome-wide significance threshold was set at P < 5 × 10−8. The meta-analysis, comprising 1504 participants, identified 242 significant SNPs across 3 genomic loci, with 99.6% of these located within known loci on chromosomes 10 (top SNP: rs58800757, P = 4.27 × 10−13) and 16 (top SNP: rs9925964, P = 9.97 × 10−16). Adjustment for the VKORC1 SNP -1639G>A revealed an additional locus on chromosome 2 (top SNPs rs116057875/rs115254730/rs115240773, P = 3.64 × 10−8), implicating the MALL gene, that could indirectly influence warfarin response through interactions with caveolin-1. In conclusion, we reaffirmed the importance of CYP2C9 and VKORC1 in influencing warfarin dose requirements, and identified a new locus (MALL), that still requires direct evidence of biological plausibility.
- 9 October 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (20) , 5248-5261
Open AccessMeta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry
Warfarin dose requirements are highly variable because of clinical and genetic factors. Although genetic variants influencing warfarin dose have been identified in European and East Asian populations, more work is needed to identify African-specific genetic variants to help optimize warfarin dosing. We performed genome-wide association studies (GWASs) in 4 African cohorts from Uganda, South Africa, and Zimbabwe, totaling 989 warfarin-treated participants who reached stable dose and had international normalized ratios within therapeutic ranges. We also included 2 African American cohorts recruited by the International Warfarin Pharmacogenetics Consortium (n = 316) and the University of Alabama at Birmingham (n = 199). After the GWAS, we performed standard error-weighted meta-analyses and then conducted stepwise conditional analyses to account for known loci in chromosomes 10 and 16. The genome-wide significance threshold was set at P < 5 × 10−8. The meta-analysis, comprising 1504 participants, identified 242 significant SNPs across 3 genomic loci, with 99.6% of these located within known loci on chromosomes 10 (top SNP: rs58800757, P = 4.27 × 10−13) and 16 (top SNP: rs9925964, P = 9.97 × 10−16). Adjustment for the VKORC1 SNP -1639G>A revealed an additional locus on chromosome 2 (top SNPs rs116057875/rs115254730/rs115240773, P = 3.64 × 10−8), implicating the MALL gene, that could indirectly influence warfarin response through interactions with caveolin-1. In conclusion, we reaffirmed the importance of CYP2C9 and VKORC1 in influencing warfarin dose requirements, and identified a new locus (MALL), that still requires direct evidence of biological plausibility.
- 1 October 2024
- Published by Medpharm Publications in SA Pharmaceutical Journal
- Vol. 91 (5) , 22-24
The GLP-1 receptor agonists: what’s all the (cardiovascular) hype about?
Over four million people in South Africa are estimated to have diabetes. People diagnosed with diabetes have an increased risk of developing cardiovascular disease. Safety trials conducted on novel hypoglycaemic agents suggest that glucagon-like peptide-1 ...
- 1 October 2024
- Published by Medpharm Publications in SA Pharmaceutical Journal
- Vol. 91 (5) , 22-24
The GLP-1 receptor agonists: what’s all the (cardiovascular) hype about?
Over four million people in South Africa are estimated to have diabetes. People diagnosed with diabetes have an increased risk of developing cardiovascular disease. Safety trials conducted on novel hypoglycaemic agents suggest that glucagon-like peptide-1 ...
- Open Access
- 1 September 2024
- Published by AOSIS in Southern African Journal of Anaesthesia and Analgesia
- Vol. 30 (4) , 100-102
Adrenaline or noradrenaline for spinal hypotension during caesarean section – beware; the cure may be worse than the disease
- 1 September 2024
- Published by AOSIS in Southern African Journal of Anaesthesia and Analgesia
- Vol. 30 (4) , 100-102
Open AccessAdrenaline or noradrenaline for spinal hypotension during caesarean section – beware; the cure may be worse than the disease
- Open Access
- 4 December 2023
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 113 (12) , 29
Wrong-route drug administration errors: A review of the literature
Oral drug formulations and enteral feeds may inadvertently be administered intravenously. Intravenous medications may be inadvertently administered intra-arterially. These examples of wrong-route drug administration errors have the potential to cause significant organ dysfunction and even death. This narrative review aims to explore the pathophysiological mechanisms underlying such errors and investigate preventive strategies and potential therapeutic options.
- 4 December 2023
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 113 (12) , 29
Open AccessWrong-route drug administration errors: A review of the literature
Oral drug formulations and enteral feeds may inadvertently be administered intravenously. Intravenous medications may be inadvertently administered intra-arterially. These examples of wrong-route drug administration errors have the potential to cause significant organ dysfunction and even death. This narrative review aims to explore the pathophysiological mechanisms underlying such errors and investigate preventive strategies and potential therapeutic options.